

S.M. Kawut is a consultant for Gilead, Actelion, Pfizer, Novartis, Merck, Ikaria and Bayer, and has received funding for clinical trials and observational studies from Actelion and Gilead.

D.J. Lederer serves on Steering Committees for clinical trials in IPF for Intermune and Gilead and serves on Advisory Panels for Gilead and ImmuneWorks. He is a steering committee member for ASCEND, sponsored by Intermune, a study investigating Pirfenidone in Idiopathic Pulmonary Fibrosis.